FDA has recently approved Contrave (Naltrexone hydrochloride and Bupropion hydrochloride extended-release tablets). Contrave is indicated for the treatment of:
a. Management of smoking cessation.
b. Treatment of seizure.
c. Management of chronic weight reduction.
d. Treatment of atypical depression.
e. Management of an opioid abuse.
Answer: Management of chronic weight reduction. The U.S. Food and Drug Administration today approved Contrave (Naltrexone hydrochloride and Bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).
The most common adverse reactions reported with Contrave include nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea.